Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

Challenges, and opportunities, abound

December 2025—When this column comes out, it will be nearly the end of 2025. It’s a good time to think about the challenges we have been facing—and the opportunities we will have in the coming years to address them. The CAP is no stranger to challenges, and neither are its members. There’s a lot going on in the world and in the health care markets that directly affects what we do. I believe that if we face these challenges head-on, we can find ways to improve laboratory quality and our ability to care for patients, all while strengthening the CAP as an organization.

Clinical pathology selected abstracts

December 2025—The American Gastroenterological Association formalized, in 2020, iron-deficiency anemia recommendations for postmenopausal women and for men, which include esophagogastroduodenoscopy and colonoscopy, or bidirectional endoscopy. This guideline only conditionally recommended that bidirectional endoscopy be performed on premenopausal women, who are more likely to have iron-deficiency anemia (IDA) due to menorrhagia. The association also advised revising the World Health Organization’s recommended iron-deficiency diagnostic threshold of 15 ng/mL or lower ferritin to 45 ng/mL or lower. The authors used population-representative data from the National Health and Nutrition Examination Survey (NHANES) to assess the role of these recommendations in IDA prevalence estimates and management in the United States.

Anatomic pathology selected abstracts

December 2025—Unusual morphologic patterns of breast carcinoma can raise diagnostic consideration for metastasis or special breast cancer subtypes and, thereby, impact clinical management and treatment. The authors conducted a study in which they described rare invasive breast cancers that mimic serous carcinoma of the gynecologic tract (serous-like breast carcinomas, SLBC) and characterized their clinicopathologic, immunophenotypic, and genetic features. The patients evaluated in the study were female (n = 15; median age, 49 years) and did not have a history of gynecologic malignancy. SLBC were characterized histologically by angulated, branched, sometimes anastomosing glands with micropapillary or pseudopapillary luminal projections in desmoplastic stroma. Most SLBC were triple negative (n = 10) or HER2 positive (n = 2) and grade 2 or 3, while some were estrogen receptor low positive/HER2 negative and low grade (n = 3). CK5/6 was positive irrespective of grade or receptor status (10 of 10).

Molecular pathology selected abstracts

Two studies explore the evolution of Mycobacterium tuberculosis and the significance of GATA1 mutations in children with Down syndrome. The first study reveals diversity in virulence gene expression across Mtb clinical isolates, with variants in the regulator whiB6 linked to decreased expression of virulence factors and increased transmission of drug-resistant strains. The second study investigates the clinical significance of GATA1 mutations in neonates with Down syndrome, finding that the presence of GATA1s mutations at birth is a strong predictor of myeloid leukemia associated with Down syndrome (ML-DS).

Newsbytes

December 2025—Mayo Clinic recently introduced Mayo Clinic Platform_Insights, an offering designed to advance the adoption of artificial intelligence by giving health care organizations around the world access to Mayo Clinic’s digital expertise, data-driven insights, and clinical knowledge. “When organizations partner with us, they gain access to proven clinical and administrative solutions and the technical framework to integrate them seamlessly,” according to a press statement from Maneesh Goyal, chief operating officer for Mayo Clinic Platform, an initiative that brings together health systems, innovators, and researchers to support responsible AI development worldwide.

Q&A column

December 2025
Q. Now that the CMS allows direct observation for competency assessment to be performed virtually, does the CAP also allow it? If so, can you provide guidance? Read answer.

Q. We have implemented quality control at 10x in accordance with the Westgard rules. I use three levels of QC. If the results of two levels of QC are moving properly above and below the mean and only one level is showing a trend of a 10x rule violation, what corrective action should I take? Read answer.

Put It on the Board

December 2025—A new Clinical and Laboratory Standards Institute document on external laboratory transport is expected to be released early next year. “It’s the first comprehensive framework for evaluating external specimen transport systems,” says Joe Wiencek, PhD, D(ABCC), document development chair and medical director and associate professor of pathology, microbiology, and immunology at Vanderbilt University Medical Center.

Gold Standard Dx launches AIX1000 2.1

December 2025—Gold Standard Diagnostics has released version 2.1 of its flagship AIX1000 RPR automation platform. This release introduces extra high titer capability, supporting screens and titers up to 1:2048. The expanded titer range aims to empower laboratories to more accurately track antibody levels over time, improving clinical decision-making and supporting public health initiatives focused on syphilis control and eradication. The test system meets the 2024 CDC Laboratory Recommendations for Syphilis Testing.

Bio-Rad launches enhanced Liquichek opiate control

December 2025—Bio-Rad Laboratories has launched an enhanced version of its Liquichek opiate control. This version includes updated fentanyl target levels optimized for clinically relevant cutoffs across major chemistry platforms. It contains eight opioid drugs or drug metabolites at concentrations above and below assay cutoffs as recommended by the U.S. Substance Abuse and Mental Health Services Administration, other agencies, and reagent manufacturers.

MARKETPLACE

TRENDING